0
0
9/14/23 at 5:57pm
Organization
FierceBiotech
Author
Max Bayer
50 words
0
Comments
As the TIGIT class gets closer to finally seeing clinical success, Bristol Myers Squibb is trimming one of its candidates. | As the TIGIT class gets closer to possible clinical success, Bristol Myers Squibb is trimming one of its candidates.
You are the first to view
https://www.fiercebiotech.com/biotech/bms-calls-it-quits-anti-tigit-and-handful-other-early-mid-stage-meds
Create an account
or login to join the discussion